title: [Cost Effectiveness of Treatments of Psoriasis with a PASI 75 and one Period of 12 Weeks].
abstract: OBJECTIVE
  The objective was to evaluate the efficiency (relation between the cost and the results in health) of the treatments in psoriasis, seeking a higher quality of economic evaluations, consistency and transparency in these studies.
  
  
  METHODS
  We developed a model of economic evaluation in psoriasis collecting all the many direct and indirect costs of each treatment. The effectiveness indicator used was Psoriasis Area Severity Index [PASI 75] which is generally acceptable in studies of psoriasis. The effectiveness indicator was a PASI 75.Subsequently we calculated the Incremental Cost-Effectiveness Ratio (ICER) for the period of 12 weeks and PASI 75, ordering treatments by level of effectiveness at the expense of treatment costs.
  
  
  RESULTS
  The most cost effective treatment was methotrexate (ICER -7.5) followed by acitretin (ICER 29.5). The least cost has proved effective PUVA (ICER 4,651), followed by UVB narrow band (2,886.1).
  
  
  CONCLUSIONS
  when taking into account both direct and indirect costs together with efficiency, methotrexate is the most cost effective treatment.
authors.affiliation: Servicio de Dermatología. Hospital Universitario Puerta de Hierro. Madrid.feralfarol@yahoo.es.
authors.forename: Fernando
authors.initials: F
authors.lastname: Alfageme Roldán
authors.affiliation: Departamento de Economía Aplicada. Universidad Autónoma de Madrid. España.
authors.forename: Almudena
authors.initials: A
authors.lastname: Bermejo Hernando
authors.affiliation: Departamento de Análisis Económico I. Universidad Nacional de Educación a Distancia. España.
authors.forename: José Luís
authors.initials: JL
authors.lastname: Calvo González
authors.affiliation: Departamento de Administración de Servicios de Enfermería. Universidad Nacional de Educación a Distancia. España.
authors.forename: Pilar
authors.initials: P
authors.lastname: Marqués Sánchez
mesh_terms: D017255:Acitretin / Q000191:economics / Q000627:therapeutic use; D000068879:Adalimumab / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D016572:Cyclosporine / Q000191:economics / Q000627:therapeutic use; D000068800:Etanercept / Q000191:economics / Q000627:therapeutic use; D017048:Health Care Costs; D006801:Humans; D007166:Immunosuppressive Agents / Q000191:economics / Q000627:therapeutic use; D000069285:Infliximab / Q000191:economics / Q000627:therapeutic use; D008727:Methotrexate / Q000191:economics / Q000627:therapeutic use; D018803:Models, Economic; D011701:PUVA Therapy / Q000191:economics; D011565:Psoriasis / Q000188:drug therapy*; D012720:Severity of Illness Index; D013030:Spain; D013997:Time Factors; D016896:Treatment Outcome; D014467:Ultraviolet Therapy / Q000191:economics; D000069549:Ustekinumab / Q000191:economics / Q000627:therapeutic use
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D000069285:Infliximab; D000069549:Ustekinumab; D000068879:Adalimumab; D017255:Acitretin; D000068800:Etanercept; D008727:Methotrexate
keywords: Adalimumab; Cost-Effectiveness Analysis; Economic Evaluation; Infliximab; Methotrexate; Psoriasis; Spain; Ustekinumab